SlideShare una empresa de Scribd logo
1 de 20
PostGenetics Medicine Đurđica Ugarković Ruđer Bošković Institute Zagreb, Croatia
The age of classical genetics in the first half of the 20th Century yielded to  t he Modern era of molecular genetics by discovery of the structure of DNA  (1953).  The term ‘Genetics’ was coined  by William Bateson on  1905  T he pre-classical era of Genetics began with Mendel 40 years earlier (1865).  Then followed two decades   of intensified focus on protein coding DNA .
The term  “Junk” DNA , originally coined by  Susumu  Ohno (1972) to describe  repetitive satellite DNA elements, became a generic term for non-protein  coding DNA.  With  protein  coding regions appearing to occupy <5% of the human genome, the majority  of approx.  95%  of DNA, reffered as  “Junk” DNA ,  was largely ignored as  u npromising   terrain for inquiry   With completion of the Human Genome Project, first announced in 2000,  “ Junk” DNA was found to comprise 98.7% of the sequenced genome, with only an estimated   26,000-30,000 genes comprising the 1.3% protein coding sequence
In the 20th Century it was believed that genetic associations with diseases would be explained by ‘mutations’ in protein-coding genes, and would be ‘solved’ by complete sequencing of genic DNA.  All  higher  organisms   have a similar number of genes. The main DNA  d ifference   between species across this broad evolutionary   time-scale is  their non-protein   coding genetic content. The Human Genome Project failed to meet the expectations of those who  sought a genic explanation of genetic risk to many common diseases.
There are about  25 ,000  genes in the human genome, but there are at least  150,000  different genetic disorders . We  can't just look   at the genes that code for proteins, you've got to look at the surrounding regulatory regions, as  w ell   in the 'junk ” . The challenge for the 21st century is to accept that gene typing alone has  been unable to explain genetic associations between many, perhaps most, diseases and genes.  New paradigms are needed.
In this PostGene era, we have established  I nternational  P ostGenetics Society (IPGS) to promote awareness of Junk   DNA’s central role in an integrative view of the  genome,   much broader than  protein  genes   alone. T he International PostGenetics Society (IPGS)   was established  in 2005,  to give priority by an International Organization to   inquiry beyond  protein-coding  g enes   http://www.junkdna.com/postgenetics/ IPGS also serves to inform government and the private sector of the utility  of total genome information in all aspects of PostGenetics;  “ PostGenetics Medicine” , and the integration of &quot;biotechnology,  n anotechnology   and information technology&quot;.
At European Inaugural Conference 2006,   IPGS asserted that Genetics had  moved beyond Genes, opening the gateway towards unravelling diseases  beyond the gene definition as priority by funding agencies and other organizations.   This paradigm shift (Gene-PostGene) affects  “PostGenetics Medicine”  –  vital for a vast segment of humanity
Policy towards PostGenetics Medicine . The new domain, proposed as  “PostGenet ics  Medicine”,  targets “Junk” DNA  Diseases   as “PostGene Diseases” in which hereditary / genetic elements are  involved in formerly “Junk” DNA.  Increasing evidence for diseases originating in non-protein coding DNA  requires an urgent  PostGenetics Study Program , leading to substantial  increase in organizational and funding support for   R&D in the field .   The IPGS  wants  to generate scientific,   political and community awareness  of the potential of PostGenetics research to throw   new light on   common  and rare “non-coding   DNA” diseases .
Powerful tools  of  gene discovery and analysis developed over the past 35  years  h ave   transformed medicine ;  P ost-genetics   now promises to give the revolution new impetus.
MHC/HLA .   The inadequacy of the gene paradigm is most evident in the Major Histocompatibility Complex and its association with allergy and autoimmunity .   MHC comprises 220 genes with so far about 100 human diseases associated with the MHC/HLA complex.  For all, with one possible exception (celiac disease), the  mechanisms underlying the associations remain unknown
Intensifying search for only coding sequencing may be insufficient,   if not misguided.   A new emerging paradigm is that non-coding sequences and “Junk DNA” through regulating higher order DNA  s tructure   contributes together with HLA gene  polymorphisms in regulat ing  T cell   function in allergy and autoimmunity
[object Object],[object Object],[object Object],[object Object],Non-coding DNA/RNA in Cancer Non-coding RNA has made an appearance as a critical factor in cancer initiation  and  p rogression . Three key areas are emerging:
Literally “on” genes, refers to all modifications to genes other than changes in the  DNA sequene itself B iological complexity depends less on gene number, and more on how those genes are used (expressed),  which is largely due to epigenetic mechanisms Epigenetic changes are heritable and effect gene expression Most cancers involve epigenetic modifications Different  biological molecules might bind to chromatin elements, influencing function by altering structure. Non- coding RNA in  Epigenetics
microRNAs D eregulation of microRNAs in cancer  is  associated with loss of suppressor gene  function or gain of oncogene function that are associated with patient prognosis In addition, non-coding RNAs have been shown to   contribute to embryonic and tissue   stem cell fate,   and we predict that they will also be found to regulate the fate of tumor stem cells or “tumor-initiating cells” in cancer.  A microRNA directly regulates a gene implicated in human cancers . Human cancers are characterized by widespread reduction in microRNA gene  expression, but what role does this have in the pathobiology of the disease?  A new study proves that reduction in microRNA expression does indeed promote tumorigenesis, changing the way we think about cancer.   MicroRNAs  act  as tumor suppressors 
microRNA knockout uncovers critical roles in immune system   Cells of the immune system in the knockout mice do not work as well as normal  cells and the mice develop symptoms similar to those of human autoimmune  disease.  They develop changes to lung tissue, with scarring that is similar to some  human systemic autoimmune disorders.  Knockout mice  are also less able to resist infection by bacteria, such as  Salmonella
(3) Polymorphisms in non-coding regions sometimes far upstream   of exons that regulate   gene expression and translational initiation. (2) Mutations and rearrangements in non-coding mitochondrial DNA such the  mtDNA D loop are found in some carcinomas that may regulate apoptosis susceptibility  Non-coding DNA in Cancer
Prostate Cancer Three separate groups of scientists have pinpointed  seven variations in DNA  that definitely increase a person's risk of prostate cancer. All of the variants are found  on the same chromosome.  But  don't call them &quot;prostate cancer genes&quot; —the reason scientists couldn't find those before, it seems, is that  the culprits turned out not to be genes at all.  Instead, they are found in so-called &quot;junk DNA,&quot; portions of the genome that don't make proteins .  &quot;What these variants are doing inside the cell is still a big question,&quot;
Alzheimer’s disease   (AD) ,  a major cause of dementia affecting 4 million people in   the USA, may have  a PostGenetic s  component .   While malfunctions   of the beta-Amyloid precursor, presenilin-1 and -2 genes,  a nd   the presence of epsilon4 allele of apolipoprotein E, are known risk factors for  s usceptibility   to AD, not all studies support gene associations with A D There have been suggestions of evidence for a link between AD and  anterior-pharynx defective-1 genes polymorphisms .
Time to Act .   The burgeoning evidence for non-coding DNA/RNA governing growth  and differentiation clearly indicates that it is time for the world agencies to develop focused PostGenetics R&D policies, such as the IPGS-proposed “ PostGenetics Study Program”, Journal and Conferences , to propel the former field of “Junk DNA” into a new functional realm, coordinating individuals, organizations and disease awareness advocacy groups.  This  PostModern expansion of   Modern Genetics will accelerate understanding of  human diseases and benefit the world.
It is certainly a fact of today, that a good number of deadly diseases (e.g. types of cancer) originate from &quot;regulatory DNA&quot;, for which no  &quot;gene discovery&quot; is likely to find a solution - as there may be no &quot;gene“ to look   for, but rathe r  “non-gene discovery&quot; appears to be a &quot;must&quot; Conclusion In all likelihood, &quot;Genetics&quot;, having turned 100 years old in 2005 may  wishes to redefine itself in the parent field of Genomics and in an  establishment of PostGenetics as the most rapidly advancing sub-field of Genomics

Más contenido relacionado

La actualidad más candente

Understanding cancer -- patient-genetic_background
Understanding cancer  -- patient-genetic_backgroundUnderstanding cancer  -- patient-genetic_background
Understanding cancer -- patient-genetic_background
Boadicea123
 
Heinrich_et_al-2003-International_Journal_of_Cancer
Heinrich_et_al-2003-International_Journal_of_CancerHeinrich_et_al-2003-International_Journal_of_Cancer
Heinrich_et_al-2003-International_Journal_of_Cancer
Bianca Heinrich
 
5. identificacion de genes
5. identificacion de genes5. identificacion de genes
5. identificacion de genes
Rafael Ospina
 

La actualidad más candente (20)

Application of genetic mapping
Application of genetic mappingApplication of genetic mapping
Application of genetic mapping
 
When viruses are beneficial
When viruses are beneficialWhen viruses are beneficial
When viruses are beneficial
 
Cancer genome (2)
Cancer genome (2)Cancer genome (2)
Cancer genome (2)
 
Proof of concept of WGS based surveillance: meningococcal disease
Proof of concept of WGS based surveillance: meningococcal diseaseProof of concept of WGS based surveillance: meningococcal disease
Proof of concept of WGS based surveillance: meningococcal disease
 
Oncogenesis / Carcinogenesis
Oncogenesis / CarcinogenesisOncogenesis / Carcinogenesis
Oncogenesis / Carcinogenesis
 
How to transform genomic big data into valuable clinical information
How to transform genomic big data into valuable clinical informationHow to transform genomic big data into valuable clinical information
How to transform genomic big data into valuable clinical information
 
Human cardiac gene therapy
Human cardiac gene therapyHuman cardiac gene therapy
Human cardiac gene therapy
 
forensic molecular biology
forensic molecular biologyforensic molecular biology
forensic molecular biology
 
Understanding cancer -- patient-genetic_background
Understanding cancer  -- patient-genetic_backgroundUnderstanding cancer  -- patient-genetic_background
Understanding cancer -- patient-genetic_background
 
Human Endogenous Retrovirus (paper)
Human Endogenous Retrovirus (paper)Human Endogenous Retrovirus (paper)
Human Endogenous Retrovirus (paper)
 
DNA REPLICATION NEWS
DNA REPLICATION NEWSDNA REPLICATION NEWS
DNA REPLICATION NEWS
 
Bioinformatics in dermato-oncology
Bioinformatics in dermato-oncologyBioinformatics in dermato-oncology
Bioinformatics in dermato-oncology
 
Scanned abstract from the proceedings
Scanned abstract from the proceedingsScanned abstract from the proceedings
Scanned abstract from the proceedings
 
Professor Akseli Hemminki presents on gene therapy and oncolytic viruses
Professor Akseli Hemminki presents on gene therapy and oncolytic virusesProfessor Akseli Hemminki presents on gene therapy and oncolytic viruses
Professor Akseli Hemminki presents on gene therapy and oncolytic viruses
 
Lombardi et al: XMRV/CFS Inflammatory Signature
Lombardi et al: XMRV/CFS Inflammatory SignatureLombardi et al: XMRV/CFS Inflammatory Signature
Lombardi et al: XMRV/CFS Inflammatory Signature
 
Viruses and viral diseases and oncogenesis
Viruses and viral diseases and oncogenesisViruses and viral diseases and oncogenesis
Viruses and viral diseases and oncogenesis
 
cancer
cancercancer
cancer
 
Heinrich_et_al-2003-International_Journal_of_Cancer
Heinrich_et_al-2003-International_Journal_of_CancerHeinrich_et_al-2003-International_Journal_of_Cancer
Heinrich_et_al-2003-International_Journal_of_Cancer
 
Carcinogenic agents and their cellular interaction
Carcinogenic agents and their cellular interactionCarcinogenic agents and their cellular interaction
Carcinogenic agents and their cellular interaction
 
5. identificacion de genes
5. identificacion de genes5. identificacion de genes
5. identificacion de genes
 

Similar a POSTGENETICS MEDICINE

thesis_final dhwani.docx
thesis_final dhwani.docxthesis_final dhwani.docx
thesis_final dhwani.docx
ssuser1e2788
 
Plegable biología molecular
Plegable biología molecularPlegable biología molecular
Plegable biología molecular
Sara Puche Gomez
 
Plegable biología molecular
Plegable biología molecularPlegable biología molecular
Plegable biología molecular
Sara Puche Gomez
 
Novel Compound to Halt Virus replication Identified AND Spasticity Gene Findi...
Novel Compound to Halt Virus replication Identified AND Spasticity Gene Findi...Novel Compound to Halt Virus replication Identified AND Spasticity Gene Findi...
Novel Compound to Halt Virus replication Identified AND Spasticity Gene Findi...
Nora Piedad Velasquez
 
A review on genetic disorders and syndromes biochemistry and molecular biolo...
A review on genetic disorders and syndromes biochemistry and  molecular biolo...A review on genetic disorders and syndromes biochemistry and  molecular biolo...
A review on genetic disorders and syndromes biochemistry and molecular biolo...
M. Luisetto Pharm.D.Spec. Pharmacology
 
Plegable biología molecular
Plegable biología molecularPlegable biología molecular
Plegable biología molecular
Sara Puche Gomez
 

Similar a POSTGENETICS MEDICINE (20)

Human genome project 1
Human genome project 1Human genome project 1
Human genome project 1
 
Dna is not destiny
Dna is not destinyDna is not destiny
Dna is not destiny
 
DNA Methylation & C Value.pdf
DNA Methylation & C Value.pdfDNA Methylation & C Value.pdf
DNA Methylation & C Value.pdf
 
Genetic factors
Genetic factorsGenetic factors
Genetic factors
 
Thesis On Psoriasis
Thesis On PsoriasisThesis On Psoriasis
Thesis On Psoriasis
 
Upb molecular journal
Upb molecular journalUpb molecular journal
Upb molecular journal
 
thesis_final dhwani.docx
thesis_final dhwani.docxthesis_final dhwani.docx
thesis_final dhwani.docx
 
Plegable biología molecular
Plegable biología molecularPlegable biología molecular
Plegable biología molecular
 
Human genome project and elsi
Human genome project and elsiHuman genome project and elsi
Human genome project and elsi
 
Genomics in Society: Genomics, Preventive Medicine, and Society
Genomics in Society: Genomics, Preventive Medicine, and SocietyGenomics in Society: Genomics, Preventive Medicine, and Society
Genomics in Society: Genomics, Preventive Medicine, and Society
 
Plegable biología molecular
Plegable biología molecularPlegable biología molecular
Plegable biología molecular
 
Novel Compound to Halt Virus replication Identified AND Spasticity Gene Findi...
Novel Compound to Halt Virus replication Identified AND Spasticity Gene Findi...Novel Compound to Halt Virus replication Identified AND Spasticity Gene Findi...
Novel Compound to Halt Virus replication Identified AND Spasticity Gene Findi...
 
Plegable biomol pdf2
Plegable biomol pdf2Plegable biomol pdf2
Plegable biomol pdf2
 
A review on genetic disorders and syndromes biochemistry and molecular biolo...
A review on genetic disorders and syndromes biochemistry and  molecular biolo...A review on genetic disorders and syndromes biochemistry and  molecular biolo...
A review on genetic disorders and syndromes biochemistry and molecular biolo...
 
Plegable biología molecular
Plegable biología molecularPlegable biología molecular
Plegable biología molecular
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
Dna repair mechanism
Dna repair mechanismDna repair mechanism
Dna repair mechanism
 
Bioinformatics
BioinformaticsBioinformatics
Bioinformatics
 
Genetic transcription
Genetic transcriptionGenetic transcription
Genetic transcription
 
DNA structure, genes and its chemical composition
DNA structure, genes and its chemical compositionDNA structure, genes and its chemical composition
DNA structure, genes and its chemical composition
 

Más de inemet

Más de inemet (20)

EUFEPS and European Initiatives in Pharmaceutical Sciences
EUFEPS and European Initiatives in Pharmaceutical SciencesEUFEPS and European Initiatives in Pharmaceutical Sciences
EUFEPS and European Initiatives in Pharmaceutical Sciences
 
Legal requirements for generics and abridged products and bioequivalence
Legal requirements for generics and abridged products and bioequivalenceLegal requirements for generics and abridged products and bioequivalence
Legal requirements for generics and abridged products and bioequivalence
 
Significance of BA/BE studies in drug research and evaluation of different as...
Significance of BA/BE studies in drug research and evaluation of different as...Significance of BA/BE studies in drug research and evaluation of different as...
Significance of BA/BE studies in drug research and evaluation of different as...
 
The role of dissolution in the demonstration of bioequivalence
The role of dissolution in the demonstration of bioequivalenceThe role of dissolution in the demonstration of bioequivalence
The role of dissolution in the demonstration of bioequivalence
 
Future trends and perspectives in modern pharmaceutical biotechnology
Future trends and perspectives in modern pharmaceutical biotechnologyFuture trends and perspectives in modern pharmaceutical biotechnology
Future trends and perspectives in modern pharmaceutical biotechnology
 
Focussing on cytotoxic treatment alone is not enough
Focussing on cytotoxic treatment alone is not enoughFocussing on cytotoxic treatment alone is not enough
Focussing on cytotoxic treatment alone is not enough
 
Bioavailability and bioequivalence – problems and pitfalls
Bioavailability and bioequivalence – problems and pitfallsBioavailability and bioequivalence – problems and pitfalls
Bioavailability and bioequivalence – problems and pitfalls
 
Quo Vadis EU Pharmacy?
Quo Vadis EU Pharmacy?Quo Vadis EU Pharmacy?
Quo Vadis EU Pharmacy?
 
Education - Do we have a choice?
Education - Do we have a choice?Education - Do we have a choice?
Education - Do we have a choice?
 
The truth between the lines – Community pharmacists in improving the health o...
The truth between the lines – Community pharmacists in improving the health o...The truth between the lines – Community pharmacists in improving the health o...
The truth between the lines – Community pharmacists in improving the health o...
 
BY HELPING PEOPLE MY DREAM IS BECOMING TRUE
BY HELPING PEOPLE MY DREAM IS BECOMING TRUEBY HELPING PEOPLE MY DREAM IS BECOMING TRUE
BY HELPING PEOPLE MY DREAM IS BECOMING TRUE
 
SHARING VISION – TOWARDS BIOMEDICINE PARTNERS
SHARING VISION – TOWARDS BIOMEDICINE PARTNERSSHARING VISION – TOWARDS BIOMEDICINE PARTNERS
SHARING VISION – TOWARDS BIOMEDICINE PARTNERS
 
Sightseeing Pharmacy practice - The way forward
Sightseeing Pharmacy practice - The way forwardSightseeing Pharmacy practice - The way forward
Sightseeing Pharmacy practice - The way forward
 
EU telematics in the regulation of pharmaceuticals
EU telematics in the regulation of pharmaceuticalsEU telematics in the regulation of pharmaceuticals
EU telematics in the regulation of pharmaceuticals
 
Generics and Biogenerics
Generics and BiogenericsGenerics and Biogenerics
Generics and Biogenerics
 
Pharmacovigilance Workshop
Pharmacovigilance WorkshopPharmacovigilance Workshop
Pharmacovigilance Workshop
 
ARE WE USING THE RIGHT OUTCOME MEASURE TO ASCERTAIN PATIENT BENEFIT FROM DRUG...
ARE WE USING THE RIGHT OUTCOME MEASURE TO ASCERTAIN PATIENT BENEFIT FROM DRUG...ARE WE USING THE RIGHT OUTCOME MEASURE TO ASCERTAIN PATIENT BENEFIT FROM DRUG...
ARE WE USING THE RIGHT OUTCOME MEASURE TO ASCERTAIN PATIENT BENEFIT FROM DRUG...
 
Making knowledge matter: The Skills Inventory and the Competency Maps
Making knowledge matter: The Skills Inventory and the Competency MapsMaking knowledge matter: The Skills Inventory and the Competency Maps
Making knowledge matter: The Skills Inventory and the Competency Maps
 
Trigger Point – Self-medication: Patients in white coats
Trigger Point – Self-medication: Patients in white coats Trigger Point – Self-medication: Patients in white coats
Trigger Point – Self-medication: Patients in white coats
 
Pharmacy in croatia - A short overview
Pharmacy in croatia - A short overviewPharmacy in croatia - A short overview
Pharmacy in croatia - A short overview
 

Último

Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al MizharAl Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
allensay1
 
Challenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
Challenges and Opportunities: A Qualitative Study on Tax Compliance in PakistanChallenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
Challenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
vineshkumarsajnani12
 
Jual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan Cytotec
Jual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan CytotecJual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan Cytotec
Jual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan Cytotec
ZurliaSoop
 

Último (20)

Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al MizharAl Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
 
Challenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
Challenges and Opportunities: A Qualitative Study on Tax Compliance in PakistanChallenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
Challenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
 
Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024
 
Durg CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN durg ESCORTS
Durg CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN durg ESCORTSDurg CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN durg ESCORTS
Durg CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN durg ESCORTS
 
joint cost.pptx COST ACCOUNTING Sixteenth Edition ...
joint cost.pptx  COST ACCOUNTING  Sixteenth Edition                          ...joint cost.pptx  COST ACCOUNTING  Sixteenth Edition                          ...
joint cost.pptx COST ACCOUNTING Sixteenth Edition ...
 
Berhampur CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Berhampur CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGBerhampur CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Berhampur CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
 
Pre Engineered Building Manufacturers Hyderabad.pptx
Pre Engineered  Building Manufacturers Hyderabad.pptxPre Engineered  Building Manufacturers Hyderabad.pptx
Pre Engineered Building Manufacturers Hyderabad.pptx
 
Falcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business PotentialFalcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business Potential
 
New 2024 Cannabis Edibles Investor Pitch Deck Template
New 2024 Cannabis Edibles Investor Pitch Deck TemplateNew 2024 Cannabis Edibles Investor Pitch Deck Template
New 2024 Cannabis Edibles Investor Pitch Deck Template
 
JAJPUR CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN JAJPUR ESCORTS
JAJPUR CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN JAJPUR  ESCORTSJAJPUR CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN JAJPUR  ESCORTS
JAJPUR CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN JAJPUR ESCORTS
 
Putting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptxPutting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptx
 
Jual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan Cytotec
Jual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan CytotecJual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan Cytotec
Jual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan Cytotec
 
Phases of Negotiation .pptx
 Phases of Negotiation .pptx Phases of Negotiation .pptx
Phases of Negotiation .pptx
 
Buy gmail accounts.pdf buy Old Gmail Accounts
Buy gmail accounts.pdf buy Old Gmail AccountsBuy gmail accounts.pdf buy Old Gmail Accounts
Buy gmail accounts.pdf buy Old Gmail Accounts
 
Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1
 
Ooty Call Gril 80022//12248 Only For Sex And High Profile Best Gril Sex Avail...
Ooty Call Gril 80022//12248 Only For Sex And High Profile Best Gril Sex Avail...Ooty Call Gril 80022//12248 Only For Sex And High Profile Best Gril Sex Avail...
Ooty Call Gril 80022//12248 Only For Sex And High Profile Best Gril Sex Avail...
 
QSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptx
QSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptxQSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptx
QSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptx
 
Lucknow Housewife Escorts by Sexy Bhabhi Service 8250092165
Lucknow Housewife Escorts  by Sexy Bhabhi Service 8250092165Lucknow Housewife Escorts  by Sexy Bhabhi Service 8250092165
Lucknow Housewife Escorts by Sexy Bhabhi Service 8250092165
 
Horngren’s Cost Accounting A Managerial Emphasis, Canadian 9th edition soluti...
Horngren’s Cost Accounting A Managerial Emphasis, Canadian 9th edition soluti...Horngren’s Cost Accounting A Managerial Emphasis, Canadian 9th edition soluti...
Horngren’s Cost Accounting A Managerial Emphasis, Canadian 9th edition soluti...
 
SEO Case Study: How I Increased SEO Traffic & Ranking by 50-60% in 6 Months
SEO Case Study: How I Increased SEO Traffic & Ranking by 50-60%  in 6 MonthsSEO Case Study: How I Increased SEO Traffic & Ranking by 50-60%  in 6 Months
SEO Case Study: How I Increased SEO Traffic & Ranking by 50-60% in 6 Months
 

POSTGENETICS MEDICINE

  • 1. PostGenetics Medicine Đurđica Ugarković Ruđer Bošković Institute Zagreb, Croatia
  • 2. The age of classical genetics in the first half of the 20th Century yielded to t he Modern era of molecular genetics by discovery of the structure of DNA (1953). The term ‘Genetics’ was coined by William Bateson on 1905 T he pre-classical era of Genetics began with Mendel 40 years earlier (1865). Then followed two decades of intensified focus on protein coding DNA .
  • 3. The term “Junk” DNA , originally coined by Susumu Ohno (1972) to describe repetitive satellite DNA elements, became a generic term for non-protein coding DNA. With protein coding regions appearing to occupy <5% of the human genome, the majority of approx. 95% of DNA, reffered as “Junk” DNA , was largely ignored as u npromising terrain for inquiry With completion of the Human Genome Project, first announced in 2000, “ Junk” DNA was found to comprise 98.7% of the sequenced genome, with only an estimated 26,000-30,000 genes comprising the 1.3% protein coding sequence
  • 4. In the 20th Century it was believed that genetic associations with diseases would be explained by ‘mutations’ in protein-coding genes, and would be ‘solved’ by complete sequencing of genic DNA. All higher organisms have a similar number of genes. The main DNA d ifference between species across this broad evolutionary time-scale is their non-protein coding genetic content. The Human Genome Project failed to meet the expectations of those who sought a genic explanation of genetic risk to many common diseases.
  • 5. There are about 25 ,000 genes in the human genome, but there are at least 150,000 different genetic disorders . We can't just look at the genes that code for proteins, you've got to look at the surrounding regulatory regions, as w ell in the 'junk ” . The challenge for the 21st century is to accept that gene typing alone has been unable to explain genetic associations between many, perhaps most, diseases and genes. New paradigms are needed.
  • 6. In this PostGene era, we have established I nternational P ostGenetics Society (IPGS) to promote awareness of Junk DNA’s central role in an integrative view of the genome, much broader than protein genes alone. T he International PostGenetics Society (IPGS) was established in 2005, to give priority by an International Organization to inquiry beyond protein-coding g enes http://www.junkdna.com/postgenetics/ IPGS also serves to inform government and the private sector of the utility of total genome information in all aspects of PostGenetics; “ PostGenetics Medicine” , and the integration of &quot;biotechnology, n anotechnology and information technology&quot;.
  • 7. At European Inaugural Conference 2006, IPGS asserted that Genetics had moved beyond Genes, opening the gateway towards unravelling diseases beyond the gene definition as priority by funding agencies and other organizations. This paradigm shift (Gene-PostGene) affects “PostGenetics Medicine” – vital for a vast segment of humanity
  • 8. Policy towards PostGenetics Medicine . The new domain, proposed as “PostGenet ics Medicine”, targets “Junk” DNA Diseases as “PostGene Diseases” in which hereditary / genetic elements are involved in formerly “Junk” DNA. Increasing evidence for diseases originating in non-protein coding DNA requires an urgent PostGenetics Study Program , leading to substantial increase in organizational and funding support for R&D in the field . The IPGS wants to generate scientific, political and community awareness of the potential of PostGenetics research to throw new light on common and rare “non-coding DNA” diseases .
  • 9. Powerful tools of gene discovery and analysis developed over the past 35 years h ave transformed medicine ; P ost-genetics now promises to give the revolution new impetus.
  • 10. MHC/HLA . The inadequacy of the gene paradigm is most evident in the Major Histocompatibility Complex and its association with allergy and autoimmunity . MHC comprises 220 genes with so far about 100 human diseases associated with the MHC/HLA complex. For all, with one possible exception (celiac disease), the mechanisms underlying the associations remain unknown
  • 11. Intensifying search for only coding sequencing may be insufficient, if not misguided. A new emerging paradigm is that non-coding sequences and “Junk DNA” through regulating higher order DNA s tructure contributes together with HLA gene polymorphisms in regulat ing T cell function in allergy and autoimmunity
  • 12.
  • 13. Literally “on” genes, refers to all modifications to genes other than changes in the DNA sequene itself B iological complexity depends less on gene number, and more on how those genes are used (expressed), which is largely due to epigenetic mechanisms Epigenetic changes are heritable and effect gene expression Most cancers involve epigenetic modifications Different biological molecules might bind to chromatin elements, influencing function by altering structure. Non- coding RNA in Epigenetics
  • 14. microRNAs D eregulation of microRNAs in cancer is associated with loss of suppressor gene function or gain of oncogene function that are associated with patient prognosis In addition, non-coding RNAs have been shown to contribute to embryonic and tissue stem cell fate, and we predict that they will also be found to regulate the fate of tumor stem cells or “tumor-initiating cells” in cancer. A microRNA directly regulates a gene implicated in human cancers . Human cancers are characterized by widespread reduction in microRNA gene expression, but what role does this have in the pathobiology of the disease? A new study proves that reduction in microRNA expression does indeed promote tumorigenesis, changing the way we think about cancer. MicroRNAs act as tumor suppressors 
  • 15. microRNA knockout uncovers critical roles in immune system Cells of the immune system in the knockout mice do not work as well as normal cells and the mice develop symptoms similar to those of human autoimmune disease. They develop changes to lung tissue, with scarring that is similar to some human systemic autoimmune disorders. Knockout mice are also less able to resist infection by bacteria, such as Salmonella
  • 16. (3) Polymorphisms in non-coding regions sometimes far upstream of exons that regulate gene expression and translational initiation. (2) Mutations and rearrangements in non-coding mitochondrial DNA such the mtDNA D loop are found in some carcinomas that may regulate apoptosis susceptibility Non-coding DNA in Cancer
  • 17. Prostate Cancer Three separate groups of scientists have pinpointed seven variations in DNA that definitely increase a person's risk of prostate cancer. All of the variants are found on the same chromosome. But don't call them &quot;prostate cancer genes&quot; —the reason scientists couldn't find those before, it seems, is that the culprits turned out not to be genes at all. Instead, they are found in so-called &quot;junk DNA,&quot; portions of the genome that don't make proteins . &quot;What these variants are doing inside the cell is still a big question,&quot;
  • 18. Alzheimer’s disease (AD) , a major cause of dementia affecting 4 million people in the USA, may have a PostGenetic s component . While malfunctions of the beta-Amyloid precursor, presenilin-1 and -2 genes, a nd the presence of epsilon4 allele of apolipoprotein E, are known risk factors for s usceptibility to AD, not all studies support gene associations with A D There have been suggestions of evidence for a link between AD and anterior-pharynx defective-1 genes polymorphisms .
  • 19. Time to Act . The burgeoning evidence for non-coding DNA/RNA governing growth and differentiation clearly indicates that it is time for the world agencies to develop focused PostGenetics R&D policies, such as the IPGS-proposed “ PostGenetics Study Program”, Journal and Conferences , to propel the former field of “Junk DNA” into a new functional realm, coordinating individuals, organizations and disease awareness advocacy groups. This PostModern expansion of Modern Genetics will accelerate understanding of human diseases and benefit the world.
  • 20. It is certainly a fact of today, that a good number of deadly diseases (e.g. types of cancer) originate from &quot;regulatory DNA&quot;, for which no &quot;gene discovery&quot; is likely to find a solution - as there may be no &quot;gene“ to look for, but rathe r “non-gene discovery&quot; appears to be a &quot;must&quot; Conclusion In all likelihood, &quot;Genetics&quot;, having turned 100 years old in 2005 may wishes to redefine itself in the parent field of Genomics and in an establishment of PostGenetics as the most rapidly advancing sub-field of Genomics